Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
The price of Twist Bioscience Corp (NASDAQ: TWST) closed at $26.75 in the last session, down -1.00% from day before closing price of $27.02. In other words, the price has decreased by -$1.00 from its previous closing price. On the day, 1.43 million shares were traded. TWST stock price reached its highest trading level at $27.27 during the session, while it also had its lowest trading level at $26.2.
Ratios:
We take a closer look at TWST’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 3.60 and its Current Ratio is at 3.90. In the meantime, Its Debt-to-Equity ratio is 0.16 whereas as Long-Term Debt/Eq ratio is at 0.13.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, Wolfe Research on December 13, 2024, initiated with a Outperform rating and assigned the stock a target price of $60.
On June 04, 2024, Guggenheim started tracking the stock assigning a Buy rating and target price of $53.
Goldman Upgraded its Neutral to Buy on January 17, 2024, whereas the target price for the stock was revised from $25 to $45.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Sep 22 ’25 when Cho Dennis sold 233 shares for $27.56 per share. The transaction valued at 6,421 led to the insider holds 102,710 shares of the business.
Green Paula sold 295 shares of TWST for $8,130 on Sep 22 ’25. The SVP of Human Resources now owns 124,542 shares after completing the transaction at $27.56 per share. On Sep 22 ’25, another insider, Leproust Emily M., who serves as the Chief Executive Officer of the company, sold 1,704 shares for $27.56 each. As a result, the insider received 46,962 and left with 633,036 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TWST now has a Market Capitalization of 1614654720 and an Enterprise Value of 1457006720. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.46 while its Price-to-Book (P/B) ratio in mrq is 3.37. Its current Enterprise Value per Revenue stands at 4.022 whereas that against EBITDA is -12.196.
Stock Price History:
The Beta on a monthly basis for TWST is 2.39, which has changed by -0.42336708 over the last 52 weeks, in comparison to a change of 0.15101504 over the same period for the S&P500. Over the past 52 weeks, TWST has reached a high of $55.33, while it has fallen to a 52-week low of $24.07. The 50-Day Moving Average of the stock is -7.42%, while the 200-Day Moving Average is calculated to be -28.87%.
Shares Statistics:
According to the various share statistics, TWST traded on average about 1.47M shares per day over the past 3-months and 1697290 shares per day over the past 10 days. A total of 60.17M shares are outstanding, with a floating share count of 57.63M. Insiders hold about 4.53% of the company’s shares, while institutions hold 113.35% stake in the company. Shares short for TWST as of 1756425600 were 10234719 with a Short Ratio of 8.72, compared to 1753920000 on 10437018. Therefore, it implies a Short% of Shares Outstanding of 10234719 and a Short% of Float of 19.129999.
Earnings Estimates
The market rating for Twist Bioscience Corp (TWST) is a result of the insights provided by 1.0 analysts actively involved in the assessment.The consensus estimate for the next quarter is -$0.52, with high estimates of -$0.52 and low estimates of -$0.52.
Analysts are recommending an EPS of between -$1.34 and -$1.34 for the fiscal current year, implying an average EPS of -$1.34. EPS for the following year is -$1.76, with 1.0 analysts recommending between -$1.76 and -$1.76.
Revenue Estimates
According to 6 analysts, the current quarter’s revenue is expected to be $97.38M. It ranges from a high estimate of $97.96M to a low estimate of $97M. As of the current estimate, Twist Bioscience Corp’s year-ago sales were $84.71MFor the next quarter, 6 analysts are estimating revenue of $101.39M. There is a high estimate of $103.3M for the next quarter, whereas the lowest estimate is $100M.
A total of 6 analysts have provided revenue estimates for TWST’s current fiscal year. The highest revenue estimate was $375.52M, while the lowest revenue estimate was $374M, resulting in an average revenue estimate of $374.89M. In the same quarter a year ago, actual revenue was $312.97MBased on 6 analysts’ estimates, the company’s revenue will be $441.55M in the next fiscal year. The high estimate is $445.92M and the low estimate is $436M.
